MARKET WIRECNBC • 3h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
Why SANA Stock surged +3.42% Today — RQD Quant Desk Flash
$2.72 +3.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.73
Sana Biotechnology Inc. (SANA) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $814.3M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.73 (+0.43%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-5.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SANA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY SANA SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (26% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)
FRED Regime × Technicals: 15% of 52W Range • RSI-14 at 46.1 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$2.79-18.6% Next Q
54
Q2 (-2Q)Grade C-$2.27+2.6% Next Q
51
Q3 (-1Q)Grade D$2.33+16.7% Next Q
49
CurrentGrade D$2.72-6.1% Hist 90D α
46
Trajectory: C- (54) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SANA Turnaround Squeeze
While SANA currently carries a cautious 46/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.04) and Max Pain ($2.86) forces dealer call-delta covering toward $5.76.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SANA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SANA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SANA Stock surged +3.42% Today — RQD Quant Desk Flash
Sana Biotechnology Inc. (SANA) surged +3.42% to $2.72, trading at 15% of its 52-week range ($2.22 – $5.49). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 15% of its 52-week range ($2.22 – $5.49) with RSI-14 at 46.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.72 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SANA Headlines & Catalysts
MARKET WIRECNBC • 3h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 4h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 5h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 6h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 7h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 7h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
MARKET WIREReuters • 7h ago
German ministers pledge tough action after rioters damage stores in Frankfurt - ReutersGerman ministers pledge tough action after rioters damage stores in Frankfurt Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SANA)
- ✓Walkthrough of SANA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SANA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -17.33%📐 HORIZONTAL RANGE
2026-10-30O $2.68H $2.72L $2.51C $2.72VOL 2.08M
RES: $4.23SUP: $2.09SMA50: $3.04SMA200: $3.39
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SANA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SANA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SANA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SANA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SANA)
Health Care Rank #447 of 1016
⚔️ DNA vs SANA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SANA vs. DNA, GLUE, MGTX, FDMT)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Sana Biotechnology Inc. (SANA) ranks #447 by composite RQD confidence (46/100, grade D) and #385 by equity capitalization ($814.3M). Within this direct 5-issuer industry benchmark cohort, SANA leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. SANA currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SANA
ACTIVE
Sana Biotechnology Inc. | D | 46/100 | — | — | -35.0% | +3.42% | $814.3M | Benchmark Subject |
| DNA Ginkgo Bioworks Holdings Inc. (Class A) | E | 28/100 | — | — | -35.0% | -4.35% | $819.7M | /dna-vs-sana → |
| GLUE Monte Rosa Therapeutics Inc. | E | 33/100 | — | — | -35.0% | +0.18% | $927.4M | /glue-vs-sana → |
| MGTX MeiraGTx Holdings plc | E | 27/100 | — | — | -35.0% | -0.46% | $932.1M | /mgtx-vs-sana → |
| FDMT 4D Molecular Therapeutics Inc. | D- | 40/100 | — | — | -28.3% | -1.16% | $706.0M | /fdmt-vs-sana → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001770121In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sana Biotechnology Inc. (SANA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$244.2M, operating cash flow of -$143.8M, and free cash flow of -$144.8M (+43.6% YoY). On the balance sheet, SANA closed FY2025 with $416.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$244.2M | -$143.8M | -$144.8M | $416.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$266.8M | -$223.2M | -$256.6M | $501.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$283.3M | -$253.6M | -$253.6M | — | — |
3. SANA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SANA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Sana Biotechnology Inc. (NASDAQ: SANA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.72 (+3.42% 1D, market cap $814.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SANA ranks #447 in composite RQD confidence.
How does SANA compare to DNA and GLUE in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SANA carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, DNA (Ginkgo Bioworks Holdings Inc. (Class A)) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $819.7M) and GLUE (Monte Rosa Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $927.4M). Among the 5-stock peer group, SANA leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SANA?
Per SANA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001770121), Sana Biotechnology Inc. generated $0 in revenue, -$244.2M in net income, and -$144.8M in free cash flow against $416.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SANA trading relative to its 50-day, 200-day, and 52-week technical levels?
SANA last traded at $2.72 (+3.42% on volume of 3,308,654 shares), positioning the stock -10.53% below its 50-day simple moving average ($3.04) and -19.76% below its 200-day simple moving average ($3.39). Across its 52-week range of $2.22 to $5.49, SANA sits at the 15.3% percentile with a 14-day RSI of 46.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.38 to $3.06).
SANA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SANA stock moving today?
Why SANA Stock surged +3.42% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.